Stockholm – CFI is pleased to announce that it acted as exclusive financial advisor to Bohus Biotech in its sale to Tellacq Partners and Flerie Invest.
Bohus BioTech AB is a Swedish biotechnology company with over 30 years’ experience of developing and manufacturing hyaluronic acid raw material and medical device products based on that substance. The company’s extensive efforts in R&D have resulted in a strong portfolio of products within Aesthetics, Ophthalmology and Orthopaedics. The products are sold under the company’s own brands as well as via customers’ brands on a global market.
Tellacq Partners is an investment company focused on investing in and operating European companies specialized in pharmaceuticals, medical devices, diagnostics products and healthcare. Flerie invest is an investment company focusing on venture and growth stage companies engaged in drug development and associated tools or applications tackling major medical challenges of our time.
Tellacq Partners and Flerie Invest acquire Bohus BioTech AB and its Portuguese subsidiary Bohus BioTech LDA.
This transaction closed on 11 April 2022
has acquired a majority share in
has sold its ceramics business to
its radiation measurement device business and the industrial X-ray CT device business